The following is an excerpt from a press release from Novo Nordisk. Read the full press release here.
Adults with haemophilia B who received a single dose Refixia® (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also observed a longer half-life for Refixia®. These pharmacokinetic findings were presented at the WFH 2018 World Congress in Glasgow, UK.
The trial showed that the total factor IX exposure of Refixia® in patient plasma after injection of a single dose (50 IU/kg) was 4.39-fold greater than for rFIXFc, as measured by the area under the curve (AUC). Seven days after injection, the factor IX activity in patients treated with a single dose of Refixia® was six-fold greater than that of patients treated with rFIXFc at the same dose.
“As a clinician, I know first-hand how challenging it can be to help people living with haemophilia B reach their treatment goals and be adequately protected from bleeding” said Dr Carmen Escuriola Ettingshausen of the Rhein-Main Haemophilia Centre (HZRM), Germany. “These data will help us better understand the different treatment options and choose the appropriate treatment for each patient.”
Read the press release in its entirety here.